|
|
|
|
deaths (OS) | progression or deaths (PFS) | RFS/DFS |
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population |
|
| nivolumab plus ipilimumab vs. nivolumab alone | 1 | - | - | 0.40 [0.20; 0.79], 1 RCT, I2=0% unassessable degree of certainty |
|
| nivolumab plus ipilimumab vs. placebo | 1 | - | - | 0.23 [0.12; 0.45], 1 RCT, I2=0% conclusive unassessable degree of certainty |
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive |
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population |
|
| nivolumab plus ipilimumab vs. ipilimumab alone | 2 | 0.58 [0.46; 0.74], 2 RCTs, I2=0% conclusive high degree of certainty | 0.41 [0.32; 0.53], 2 RCTs, I2=0% conclusive high degree of certainty | - |
|
| nivolumab plus ipilimumab vs. nivolumab alone | 1 | 0.65 [0.53; 0.80], 1 RCT, I2=0% unassessable degree of certainty | 0.74 [0.60; 0.92], 1 RCT, I2=0% unassessable degree of certainty | - |
| relatlimab plus nivolumab vs. nivolumab alone | 1 | - | 0.75 [0.62; 0.91], 1 RCT, I2=0% unassessable degree of certainty | - |
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant |
|
| nivolumab plus ipilimumab vs. ipilimumab alone | 1 | 1.44 [0.46; 4.49], 1 RCT, I2=0% inconclusive result | 0.38 [0.15; 0.98], 1 RCT, I2=0% unassessable degree of certainty | - |
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild |
|
| nivolumab plus ipilimumab vs. ipilimumab alone | 1 | - | 0.40 [0.23; 0.69], 1 RCT, I2=0% conclusive unassessable degree of certainty | - |
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population |
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant |